 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Transkaryotic Therapies, Inc.
 |
Transkaryotic Therapies, Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Transkaryotic's Fabry drug wins approval in Europe Aug 03 2001 11:47 AM PDT
Transkaryotic, Merck executives said up for FDA post Jul 18 2001 01:30 PM PDT
> More WIRE STORIES about this company
NEWS FROM THE STANDARD |
 |
Dell Drizzles on Nasdaq's Parade
Jan 22 2001 02:24 PM PST
PROFILE |
 |
Transkaryotic Therapies (TKT) operates at the cellular level. The firm researches gene therapies that activate malfunctioning genes, prompting them to produce proteins necessary for proper operation. It does not rely on cloned genes; instead, TKT is developing a way to graft activating DNA sequences directly onto genes, which will then reproduce properly. With Aventis, the firm is developing Dynepo, a treatment for anemia; the duo and Amgen are battling in court over the drug and its similarity to Amgen's blockbuster Epogen. TKT's Replagal, a therapy for Fabry disease, has received orphan drug status in Europe and the US. The company is also working on a product to treat hemophilia.
COMPETITION |
 |
Amgen Inc. (AMGN)
Genzyme Corporation (GENZ)
Johnson & Johnson (JNJ)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 7.20
1-Yr. Sales Growth: 84.6%
Employees: 322
Revenue per employee: $22,360.25
KEY PEOPLE |
 |
Richard F. Selden
CEO
Daniel E. Geffken
CFO
CONTACT INFO |
 |
195 Albany St.
Cambridge, MA 02139
US
Phone: 617-349-0200
Fax: 617-349-0599
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |